Arbutus Biopharma
ABUS
ABUS
59 hedge funds and large institutions have $67.4M invested in Arbutus Biopharma in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
Holders
59
Holding in Top 10
1
Calls
$501K
Puts
–
Top Buyers
| 1 | +$10.3M | |
| 2 | +$6.06M | |
| 3 | +$5.27M | |
| 4 |
CAC
Cowen and Company
New York
|
+$2.58M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$797K |
Top Sellers
| 1 | -$9.57M | |
| 2 | -$1.59M | |
| 3 | -$806K | |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$763K |
| 5 |
Renaissance Technologies
New York
|
-$257K |